Ming-Fong Lin

List of Publications by Year
in descending order

45 papers	1,543 citations	361413 20 h-index	302126 39 g-index
45 all docs	45 docs citations	45 times ranked	1911 citing authors

#	Article	IF	Citations
1	Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Molecular and Cellular Endocrinology, 2008, 295, 115-120.	3.2	191
2	Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate, 2002, 50, 222-235.	2.3	166
3	Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocrine-Related Cancer, 2006, 13, 151-167.	3.1	140
4	Expression of Human Prostatic Acid Phosphatase Correlates with Androgen-stimulated Cell Proliferation in Prostate Cancer Cell Lines. Journal of Biological Chemistry, 1998, 273, 5939-5947.	3.4	122
5	Tyrosine Phosphorylation of c-ErbB-2 Is Regulated by the Cellular Form of Prostatic Acid Phosphatase in Human Prostate Cancer Cells. Journal of Biological Chemistry, 1998, 273, 22096-22104.	3.4	78
6	Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene, 2003, 22, 6704-6716.	5.9	69
7	Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene, 2000, 19, 2664-2677.	5.9	66
8	DECREASED EXPRESSION OF CELLULAR PROSTATIC ACID PHOSPHATASE INCREASES TUMORIGENICITY OF HUMAN PROSTATE CANCER CELLS. Journal of Urology, 2001, 166, 1943-1950.	0.4	66
9	Expression of p66Shc protein correlates with proliferation of human prostate cancer cells. Oncogene, 2005, 24, 7203-7212.	5.9	55
10	Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Therapeutic Advances in Urology, 2015, 7, 388-395.	2.0	50
11	p66Shcâ€"a longevity redox protein in human prostate cancer progression and metastasis. Cancer and Metastasis Reviews, 2010, 29, 207-222.	5.9	45
12	Human Prostatic Acid Phosphatase, an Authentic Tyrosine Phosphatase, Dephosphorylates ErbB-2 and Regulates Prostate Cancer Cell Growth. Journal of Biological Chemistry, 2010, 285, 23598-23606.	3.4	45
13	p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. International Journal of Cancer, 2004, 108, 672-678.	5.1	44
14	Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. Oncotarget, 2015, 6, 3887-3903.	1.8	37
15	A novel role of Shc adaptor proteins in steroid hormone-regulated cancers. Endocrine-Related Cancer, 2009, 16, 1-16.	3.1	33
16	ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. Cellular Signalling, 2015, 27, 2261-2271.	3.6	29
17	Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells. Free Radical Biology and Medicine, 2012, 53, 95-108.	2.9	28
18	Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells. Cancer Letters, 2014, 353, 59-67.	7.2	25

#	Article	IF	Citations
19	Statin derivatives as therapeutic agents for castration-resistant prostate cancer. Cancer Letters, 2016, 383, 94-105.	7.2	24
20	Novel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer Cells. PLoS ONE, 2015, 10, e0131811.	2.5	23
21	Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 88-98.	7.4	21
22	p66Shc regulates migration of castration-resistant prostate cancer cells. Cellular Signalling, 2018, 46, 1-14.	3.6	19
23	Vitamin D3 Regulates the Formation and Degradation of Gap Junctions in Androgen-Responsive Human Prostate Cancer Cells. PLoS ONE, 2014, 9, e106437.	2.5	18
24	Shifted Golgi targeting of glycosyltransferases and Î±-mannosidase IA from giantin to GM130-GRASP65 results in formation of high mannose N -glycans in aggressive prostate cancer cells. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2891-2901.	2.4	18
25	Steroids Up-Regulate p66Shc Longevity Protein in Growth Regulation by Inhibiting Its Ubiquitination. PLoS ONE, 2011, 6, e15942.	2.5	17
26	ErbB-2 signaling in advanced prostate cancer progression and potential therapy. Endocrine-Related Cancer, 2019, 26, R195-R209.	3.1	17
27	p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. Free Radical Biology and Medicine, 2019, 139, 24-34.	2.9	15
28	p66Shc longevity protein regulates the proliferation of human ovarian cancer cells. Molecular Carcinogenesis, 2015, 54, 618-631.	2.7	12
29	Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5. BMC Cancer, 2017, 17, 179.	2.6	10
30	PROTEIN KINASE C PATHWAY IS INVOLVED IN REGULATING THE SECRETION OF PROSTATIC ACID PHOSPHATASE IN HUMAN PROSTATE CANCER CELLS. Cell Biology International, 2001, 25, 1139-1148.	3.0	9
31	Antischistosomal versus Antiandrogenic Properties of Aryl Hydantoin Ro 13-3978. American Journal of Tropical Medicine and Hygiene, 2014, 90, 1156-1158.	1.4	8
32	Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Cancer Letters, 2018, 436, 96-108.	7.2	7
33	Multifunctionality of prostatic acid phosphatase in prostate cancer pathogenesis. Bioscience Reports, 2021, 41, .	2.4	7
34	Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines. Molecular and Cellular Biochemistry, 2000, 208, 11-18.	3.1	5
35	Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression. Cell and Bioscience, 2015, 5, 38.	4.8	5
36	A novel pregnene analogs: synthesis, cytotoxicity on prostate cancer of PC-3 and LNCPa-AI cells and in silico molecular docking study. Molecular Diversity, 2021, 25, 661-671.	3.9	5

#	Article	IF	Citations
37	Combination Treatment Options for Castration-Resistant Prostate Cancer. , 0, , 59-80.		5
38	Discovery of Novel <i>N</i>-alkyl 4-anilinofuro[2,3-<i>b</i>]quinoline Derivatives (CIL-102 Derivatives) Against Castration-resistant Human Prostate Cancers. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 493-500.	1.7	4
39	Targeting treatment options for castration-resistant prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 101-120.	0.4	4
40	Multifunctionality of Prostatic Acid Phosphatase in ProstateÂ Cancer Pathogenesis. Bioscience Reports, 2021, , .	2.4	1
41	Pathological Processes Related to Redox. , 0, , 183-225.		0
42	Regulator of Gâ€protein Signaling 2 (RGS2) inhibits androgenâ€independent activation of androgen receptor in prostate cancer cells. FASEB Journal, 2006, 20, A1120.	0.5	0
43	Vasoactive intestinal peptide transactivates the androgen receptor through a PKAâ€dependent extracellular signalâ€regulated kinase pathway in prostate cancer cells. FASEB Journal, 2007, 21, .	0.5	0
44	5â€azaâ€2â€²â€deoxycytidine suppresses androgen independent prostate cancer growth by restoring RGS2 expression. FASEB Journal, 2011, 25, 802.6.	0.5	0
45	Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate Cancer Cells. Journal of Oncology Research and Therapy, 2017, 3, .	0.0	0